Quest Diagnostics Incorporated (DGX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 9 | 11 | 10 | 9 | 10 | 11 | 12 | 12 |
| Operating profit | $bn | 2 | 2 | ||||||
| Net profit | $bn | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS reported | $ | 8.75 | 9.42 | ||||||
| Operating cashflow per share | $ | 16.99 | 16.13 | ||||||
| Capex per share | $ | 4.75 | 5.04 | ||||||
| FCF per share | $ | 12.24 | 11.09 | ||||||
| Free cash flow | $bn | 1 | 1 | ||||||
| Net debt | $bn | 6 | 5 | ||||||
| Book value equity | $bn | 7 | 8 | ||||||
| Book value per share | $ | 63.45 | 67.11 | ||||||
| Number of shares | m | 113 | 112 | ||||||
| DPS (TTM paid) | $ | 3.15 | 4.18 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.83 | 25.09 | ||||||
| P/B LTM | x | 2.69 | 2.56 | ||||||
| P/S LTM | x | 1.75 | 1.67 | ||||||
| P/FCF LTM | x | 14.17 | 15.79 | ||||||
| EV/EBITDA LTM | x | 11.74 | 12.83 | ||||||
| EV/Sales LTM | x | 2.33 | 2.76 | ||||||
| Earnings Yield LTM | % | +5.04% | +3.99% | ||||||
| FCF Yield | % | +7.06% | +6.33% | ||||||
| Quality | |||||||||
| ROE | % | +13.84% | +14.49% | ||||||
| ROIC | % | +8.43% | +8.25% | ||||||
| Operating margin | % | +14.53% | +14.14% | ||||||
| Gross margin | % | +31.93% | +33.15% | ||||||
| FCF/Sales | % | +12.32% | +10.55% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +13.78% | +22.50% | ||||||
| Sales Growth YoY | % | +11.78% | +17.10% | ||||||
| Net Income Growth YoY | % | +13.89% | +21.93% | ||||||
| FCF Growth | % | +49.50% | +34.21% | ||||||
| Operating Profit Growth | % | +19.09% | +21.47% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.83% | +1.40% | ||||||
| Dividend Growth | % | +6.42% | +41.22% | ||||||
| Payout Ratio | % | +35.70% | +34.33% | ||||||
| FCF/Debt | x | 0.20 | 0.19 | ||||||
| Net Debt/EBITDA | x | 2.96 | 2.87 | ||||||
| EBIT/Net interest | x | 5.79 | 6.24 | ||||||
| Net debt/market cap | % | +33.13% | +24.39% | ||||||
| Net debt/Equity | x | 0.83 | 0.67 | ||||||
| Gross debt/equity | x | 0.96 | 0.85 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Quest Diagnostics Incorporated (DGX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free